Page results
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
University College London Hospitals (UCLH) is now administering new COVID-19 treatments for patients at highest risk in the community.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
This page provides information for patients who are due to be admitted to hospital for bowel surgery.
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
UCLH NHS Foundation Trust has once again formed a partnership with the Business Design Centre in Islington to reopen a large-scale COVID-19 vaccination centre on site from Saturday 18 December.
-
This page provides information about the WEB device and how it is used to treat cerebral (brain) aneurysms
-
Researchers at UCLH and UCL have completed the first and only randomised trial to explore a new approach to treating aggressive lung cancer.
-
This page is for cancer patients receiving immunotherapy treatment.
-
This information is for patients receiving steroids for immunotherapy toxicity.
File results
-
FOI/2024/0034 - Policies and procedures for Subject Access and Data Protection requests
-
FOI/2024/0042 - CT and MRI machines at Trust from 2019-2023
-
FOI/2024/0043 - Derogations following junior doctors strikes
-
FOI/2024/0046 - Translation and interpreting from 2019/20 to 2022/23
-
FOI/2024/0050 - Various patient transport services procured
-
FOI/2024/0053 - Pharmacy, prescribing and medicines strategy
-
FOI/2024/0056 - MRI examinations performed in 2023
-
FOI/2024/0059 - Late effects of cancer service
-
FOI/2024/0060 - Procurement contract register and procurement strategy
-
FOI/2024/0061 - 24 hour waits at A&E from 2019 to 2023